Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453101 | 0.90 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL5459777 | 0.85 | KCNH2 (0.43) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5460141 | 0.85 | KCNH2 (0.41) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5452041 | 0.83 | KCNH2 (0.42) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5457752 | 0.82 | KCNH2 (0.47) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5466419 | 0.81 | KCNH2 (0.47) | KCNH2SCN5A | |
| SCHEMBL5450712 | 0.81 | KCNH2 (0.49) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14443939 | 0.81 | KCNH2 (0.49) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5457689 | 0.79 | KCNH2 (0.45) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5450793 | 0.79 | KCNH2 (0.40) | KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | claimed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | claimed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KCNH2 2633/4885CYP1A2 773/4885CYP3A4 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.